Highest-materiality recent filing
Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility
Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.
Alector enters $125M ATM equity facility with TD Cowen
May sell up to $125M of common stock from time to time through TD Cowen in at-the-market offerings.
Alector Q4 net loss $37.3M ($0.34/share); revenue down 89% YoY; cash $256M
Q4 2025 net loss $37.3M vs $2.1M in Q4 2024; full-year net loss $142.9M ($1.39/share).
Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%
Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.
Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns
Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.
Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4
Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.
Effective upon Dr. Grasso’s resignation, Neil Berkley will be Chief Business Officer and Interim Chief Financial Officer, serving as the principal financial officer of Alector
On June 9, 2025, Dr. Marc Grasso gave notice of his decision to resign from his position as Chief Financial Officer of Alector, Inc. (“Alector”) in order to pursue other opportunities.
and Grace Wong-Sarad will be the Vice President, Accounting, serving as the principal accounting officer of Alector.
Max materiality 0.90 · Median 0.68 · Most common event earnings